摘要:
Disclosed herein are cyclic peptide derivatives of the formula ##STR1## wherein A is absent or the tripeptide radical Thr.rarw.Gly.rarw.Ala, R.sup.1 is benzyl or benzyl monosubstituted at position 4 of the aromatic ring with halo, hydroxy, lower alkyl or lower alkoxy, R.sup.2 and R.sup.4 each independently is hydrogen or lower alkyl, R.sup.3 is lower alkyl or lower alkyl monosubstituted with a hydroxy, R.sup.5 is lower alkyl, Y is oxo or thioxo and Z is hydroxy or NR.sup.6 R.sup.7 wherein R.sup.6 and R.sup.7 each independently is hydrogen or lower alkyl. The derivatives are useful for treating herpes infections.
摘要:
Disclosed herein are cyclic peptide derivatives of the formula ##STR1## wherein A is absent or the tripeptide radical Thr.rarw.Gly.rarw.Ala, R.sup.1 is benzyl or benzyl monosubstituted at position 4 of the aromatic ring with halo, hydroxy, lower alkyl or lower alkoxy, R.sup.2 and R.sup.4 each independently is hydrogen or lower alkyl, R.sup.3 is lower alkyl or lower alkyl monosubstituted with a hydroxy, R.sup.5 is lower alkyl, Y is oxo or thioxo and Z is hydroxy or NR.sup.6 R.sup.7 wherein R.sup.6 and R.sup.7 each independently is hydrogen or lower alkyl. The derivatives are useful for treating herpes infections.
摘要:
Disclosed herein are pentapeptide derivatives of the formula X--NR.sup.1 --CH(R.sup.2)--C(W)--NH--CR.sup.3 (R.sup.4)--C(W.sup.2)--NR.sup.5 --CH CH.sub.2 C(O)--Y!--C(W.sup.3)--NH--CR.sup.6 -- CR.sup.7 (R.sup.8)--COOH!--C(W.sup.4)--NH--CR.sup.9 (R.sup.10)--Z wherein X is a terminal group, for example, alkanoyl or phenylalkanoyl radicals, R.sup.1 is hydrogen, alkyl or phenylalkyl, R.sup.2, R.sup.4 and R.sup.10 are selected from amino acid or derived amino acid residues, R.sup.3, R.sup.5, R.sup.6, R.sup.7, R.sup.8 and R.sup.9 are hydrogen or alkyl or R.sup.7 and R.sup.8 are joined to form a cycloalkyl, W.sup.1, W.sup.2, W.sup.3 and W.sup.4 are oxo or thioxo, Y is, for example, an alkoxy or a mono or disubstituted amino, and Z is a terminal group, for example, COOH or CH.sub.2 OH. The derivatives are useful for treating herpes infections.
摘要:
The present invention is directed to compounds that act as analgesics and that have the structure of formula (I): ##STR1## wherein; Z is ##STR2## wherein, n is 1 or 2, and R.sub.0 is C.sub.6-12 aryl or C.sub.7-8 aralkyl; orR.sub.1 is selected from the group consisting of hydrogen; --NH--C.sub.1-6 alkyl; C.sub.1-6 alkyl; C.sub.6-12 aryl; C.sub.7-18 aralkyl; arginyl; and R.sub.30 NHC(.dbd.NH)--, wherein R.sub.30 is hydrogen, C.sub.6-12 aryl, C.sub.7-18 aralkyl, or C.sub.1-6 alkyl;R.sub.2 is hydrogen; C.sub.1-6 alkyl; or OH;R.sub.3 is C.sub.6-12 aryl; C.sub.7-18 aralkyl; --CH.sub.2 --C.sub.6 H.sub.2 R.sub.8 R.sub.9 ;or --CH.sub.2 --OHC.sub.6 HR.sub.8 R.sub.9, wherein each of R.sub.8 and R.sub.9 is independently, or hydrogen;R.sub.4 C.sub.6-12 aryl; C.sub.7-18 aralkyl; C.sub.1-12 alkyl; or a substituted or unsubstituted cyclohexyl;R.sub.5 is C.sub.1-6 alkyl; hydrogen; OH; halogen; SH; NO.sub.2 ; NH.sub.2 ; --NH--C.sub.1-6 alkyl; NH.sub.2 C (.dbd.NH--; NH.sub.2 C (.dbd.NH)--NH--; COOR.sub.31, wherein, R.sub.31 is hydrogen, or C.sub.1-6 alkyl;X is CH.sub.2 NHC(O)--; CH.sub.2 NHC(O)O; --C(O)NH--; or CH.sub.2 NH--; andL is a C.sub.1-12 alkylene chain which can be substituted with at least one substituent selected from the group consisting of; a C.sub.3 -C.sub.12 cycloalkyl containing at least one heteroatom; C.sub.1-6 alkyl; OR.sub.31 ; --NHC(O)R.sub.33 ; --OC(O)R.sub.34 --NHR.sub.35 wherein; and NR.sub.6 R.sub.7 ;with the proviso that when R.sub.5 is hydrogen, Z is ##STR3## and X is --C(O)NH--, or --CH.sub.2 NH--, then L is a C.sub.1-12 alkyl chain substituted with at least one substituent selected from the group consisting of; a C.sub.3 -C.sub.12 cycloalkyl containing at least one heteroatom; C.sub.1-6 alkyl; OR.sub.31 ; SR.sub.32 ; --NHC(O)R.sub.33 ; --OC(O)R.sub.34, --NHR.sub.35 ; and NR.sub.6 R.sub.7.
摘要翻译:PCT No.PCT / SE97 / 00315 Sec。 371日期:1997年10月6日 102(e)日期1997年10月6日PCT 1997年2月25日提交PCT公布。 第WO97 / 31940号公报 日期:1997年9月4日本发明涉及作为止痛剂的具有式(I)结构的化合物:其中: Z是其中n是1或2,R 0是C 6-12芳基或C 7-8芳烷基; 或R 1选自氢; -NH-C 1-6烷基; C 1-6烷基; C6-12芳基; C7-18芳烷基; 精氨酰 和R 30 NHC(= NH) - ,其中R 30是氢,C 6-12芳基,C 7-18芳烷基或C 1-6烷基; R2是氢; C 1-6烷基; 或OH; R3为C6-12芳基; C7-18芳烷基; -CH 2 -C 6 H 2 R 8 R 9或-CH 2 -OH C 6 H 8 R 9,其中R 8和R 9各自独立地是氢或氢; R4 C6-12芳基; C7-18芳烷基; C 1-12烷基; 或取代或未取代的环己基; R5是C1-6烷基; 氢; 哦; 卤素; SH; NO2; NH2; -NH-C 1-6烷基; NH 2 C(= NH-; NH 2 C(= NH)-NH-; COOR 31,其中R 31是氢或C 1-6烷基; X是CH 2 NHC(O) - ; CH 2 NHC(O)O; -C(O) ;或CH 2 NH-;并且L是可以被至少一个选自以下的取代基取代的C 1-12亚烷基链:包含至少一个杂原子的C 3 -C 12环烷基; C 1-6烷基; OR 31; -NHC (O)R 33; -OC(O)R 34 -NHR 35,其中;和NR 6 R 7;条件是当R 5为氢时,Z为且X为-C(O)NH-或-CH 2 NH-,则L为C1 -12烷基链,其被至少一个选自以下的取代基取代:含有至少一个杂原子的C 3 -C 12环烷基; C 1-6烷基; OR 31; SR 32; -NHC(O)R 33; -OC(O)R 34 ,-NHR 35;和NR 6 R 7。
摘要:
An ear hair removal instrument including a head, at least a portion of which its outer surface is covered with cold wax. The head is shaped and sized to be receivable in the outer ear while preventing insertion into the middle ear. A handle is mounted at its distal end to the head. In use, the head of the instrument is inserted in the outer ear so that the cold wax disposed on the head comes into contact with the ear hair. While disposed in the outer ear, the ear hair in contact with the cold wax is extracted from its follicles by simultaneously rotating and pulling the instrument.
摘要:
A thrombin inhibitor comprising a first bulky hydrophobic portion interacting with the catalytic site of thrombin responsible for proteolysis and a second portion at least maintaining the hydrophobic and acidic character of amino acids 55 to 60 of native hirudin at the C-terminal non-catalytic region of N-acetyl-hirudin45-65. Between the first and second portions is a divalent linker moiety having a chain length of at least 10 carbon atoms. Connecting the first bulky hydrophobic portion and the linker is a peptidomimetic bond. Preferably, the bulky hydrophobic portion comprises at least one amino acid of D-configuration. The compounds are useful in the treatment of thrombotic disorders.
摘要:
Disclosed herein are derivatives of atrial natriuretic peptides wherein the exocyclic N-terminal peptide segment is deleted and the two cysteinyl residues (at positions 105 and 121) of the natural sequence are replaced with a trivalent unit, --NHCH(CO--)--Q--X--Y--CH.sub.2 CH.sub.2 CO-- wherein Q is methylene, ethylene or CR'R" wherein R' and R" each independently is lower alkyl, X is oxy or thio, and Y is methylene or des-Y. The derivatives may be optionally substituted at various positions including positions 106, 107 and 124. The derivatives possess ANF-like activity and are indicated for treating hypertension and for treating pathological conditions resulting from an imbalance of body fluids and electrolytes.